摘要新型冠状病毒感染（COVID-19）的住院患者在临床救治过程中容易出现各种并发症，尤其是静脉血栓栓塞症（VTE），一旦发生，会导致患者的非预期死亡风险显著增加。近年来，国际已发布系列相关权威指南及高质量循证医学研究证据，工作组也于近期联合国内外VTE防治、重症救治、循证医学领域等多学科专家，共同制订了《新型冠状病毒感染住院患者血栓预防和抗凝管理指南》。基于此，工作组在指南的基础上对目前临床实践中亟需关注的13个临床问题进行了详细阐述，明确了标准化的操作路径，如：COVID-19住院患者的VTE风险和出血风险评估，不同严重程度的COVID-19住院患者以及合并妊娠、恶性肿瘤、基础疾病或脏器功能不全、服用抗病毒及抗炎药物、血小板减少等特殊人群的VTE预防和抗凝管理，COVID-19患者出院后的VTE预防及抗凝管理，COVID-19患者住院期间并发VTE的抗凝管理，正在进行VTE治疗且合并COVID-19患者的抗凝管理，COVID-19住院患者出血危险因素、临床分型及相应处理等。特别是参照了国际最新指南及研究证据，对于COVID-19住院患者如何准确把握标准预防剂量抗凝和治疗剂量抗凝也给出了明确的实施建议，期望能为医护人员针对COVID-19住院患者的血栓预防和抗凝管理提供标准化的操作流程和实施方案。

abstractsInpatients infected with SARS-CoV-2 are prone to various complications during clinical treatment, especially venous thromboembolism (VTE), which significantly increases the risk of unexpected death. In recent years, a series of authoritative guidelines and high-quality evidence-based medicine research evidence have been published internationally. This working group has recently formulated the Guidelines for Thrombosis Prevention and Anticoagulant Management of Hospitalized Patients with Novel Coronavirus Infection with multidisciplinary experts in the fields of VTE prevention, critical care and evidence-based medicine from international and domestic experts. Based on this, the working group elaborated on 13 clinical issues in urgent need of attention and solution in current clinical practice on the basis of the guidelines and defined standardized operational paths, including VTE risk and bleeding risk assessment in hospitalized patients with COVID-19, VTE prevention and anticoagulant management of hospitalized COVID-19 patients with different severity and special patient populations complicated with pregnancy, malignant tumors, underlying diseases or organ insufficiency, usage of antiviral and anti-inflammatory drugs or thrombocytopenia, in addition to VTE prevention and anticoagulant management of discharged COVID-19 patients, anticoagulant management of COVID-19 patients complicated with VTE during hospitalization, anticoagulant management in patients undergoing VTE therapy with COVID-19, risk factors of bleeding in hospitalized patients with COVID-19, clinical classification and corresponding management. In particular, by referring to the latest international guidelines and research evidence, this paper provides clear implementation recommendations on how to accurately determine the standard preventive dose anticoagulation and therapeutic dose anticoagulation for hospitalized patients with COVID-19. This paper is expected to provide standardized operational procedures and implementation norms for healthcare workers to managing thrombus prevention and anticoagulation in hospitalized patients with COVID-19.